Cachexia affects the majority of cancer patients with advanced disease and its treatment represents a major unmet clinical need. Muscle wasting is a key feature of the cachexia syndrome. Although studied in animal models, there are few studies in patients and none measuring muscle protein synthesis in free-living subjects at home. Here we have measured muscle protein synthesis in patients prior to undergoing surgery for upper GI cancer. We show that muscle protein synthesis is not decreased and may even be marginally increased. Our findings support the concept that a small increase in protein breakdown or altered myonuclear regeneration/loss may be the main mechanism accounting for muscle wasting in cancer patients. Our findings suggest that multimodal cachexia therapy should utilise anabolic strategies (since synthesis is not suppressed) and perhaps also target specific breakdown pathways/myonuclear regeneration to achieve maximum benefit.
Introduction
Loss of skeletal muscle mass in cancer is well described (1) (2) (3) and is a defining characteristic of the cachexia syndrome (4) . Low muscle mass is associated with a variety of clinical consequences including prolonged hospitalisation, reduced mobility and increased chemotherapy toxicity (5) . A key objective of supportive cancer care is to preserve or increase muscle mass and perhaps improve outcomes during cancer treatment. In normal day to day living, muscle mass is generally thought to be maintained by the balance between muscle protein synthesis and breakdown. An alternative process is the balance between muscle regeneration via activation of satellite cells and myo-nuclear loss via apoptosis (6) .
A reduction in muscle mass can occur due to an increase in muscle protein breakdown, a decrease in synthesis or a combination of the two and all variations have been described in animal models of cancer cachexia (7) . However, there are many limitations when extrapolating such models to the human situation, including the more acute versus chronic timescales of tumour growth and development of muscle wasting (8) . Due to the invasive nature of clinical protocols to date, there are few studies of skeletal muscle protein metabolism in human cancer cachexia and these have demonstrated either markedly reduced (9) or unchanged (2) FSR when compared with controls. In a previous study of patients with upper GI cancer cachexia, we have demonstrated that the transcriptome in human skeletal muscle demonstrates down regulation of ~1700 genes (mostly connected with cell turnover) and up-regulation of ~100 genes, none with known connections to protein degradation via the ubiquitin proteasome pathway (10) . This led to the conclusion that reduced synthesis was the likely cause of muscle wasting in such patients.
Previous studies of skeletal muscle protein synthesis in humans have used an infusion protocol with a stable isotope labelled amino acid. Under controlled conditions in a clinical research facility such protocols are ideal for estimating the short term response (2 -6 hours) to specific stimuli such as feeding or exercise, but are unsuitable for measuring skeletal muscle synthesis in individuals living in the community. An alternative method uses the oral administration of a deuterium tracer in the form Author Manuscript Published OnlineFirst on November 4, 2014; DOI: 10.1158/1078-0432.CCR- of heavy water (H 2 O). With this method, endogenous or intrinsic labelling of dispensable amino-acids occurs and the latter become incorporated into muscle protein. The predictable kinetics and long elimination half-time of body water allows a period of one to two weeks between tracer administration and muscle biopsy (11) (12) (13) (14) . Thus the participant can return home, eat normally and resume normal activity during the study period. Using such methodology skeletal muscle protein synthesis has been measured in the elderly over a 6 week period with regular tracer doses and fractional synthetic rate (FSR) found to be 1.06 %/d or 0.044%/h (15) . In young men (using a single dose over a 48 hour period) FSR was estimated at 1.45 %/day or 0.060 %/h (16). We have previously developed a protocol in healthy volunteers whereby muscle FSR was measured to be 0.058 %/h over a 1-2 week period after a single oral dose (17). The method is made possible by the use of Gas Chromatography-Pyrolysis-Isotope (GC-P-IRMS), allowing the measurement of the very low enrichments resulting from an economic dose of tracer. This single dose protocol is ideal for clinical use as it reduces the burden on the patient, it allows measurement of body composition and can be modified to include total energy expenditure. The present study aimed to measure habitual myofibrillar protein FSR in healthy volunteers versus weight-losing and weight-stable patients with cancer. Secondary aims were to compare quadriceps muscle FSR with rectus abdominis FSR and to examine the influence of muscle loss on muscle FSR.
Methods

Subjects/Protocol
The protocol received approval by the Lothian Research Ethics Committee. Written informed consent was obtained from all participants. All procedures were in accordance with International Conference on Harmonization Guidelines on Good Clinical Practise and the Helsinki Declaration. Healthy volunteers were screened using a simple health questionnaire (18) , patients planned for upper gastrointestinal cancer surgery were recruited at the Royal Infirmary Edinburgh, UK. A medical history was recorded along with current height and weight and a self reported pre-illness weight from which total weight loss was calculated. A single oral dose of 133g 70atom% of deuterium oxide was administered under supervision at the start of the protocol. Serial blood and urine samples were taken at baseline and 24 hours, 72 hours and on the final day of the study. For the healthy volunteers, a quadriceps biopsy was taken under local anaesthetic using a Bergstrom needle and subsequently snap frozen in liquid nitrogen. Combined quadriceps and rectus abdominis biopsies were taken under general anaesthesia at the start of surgery in the cancer patients.
Laboratory methods
The procedure for preparation and analysis of samples was performed as previously described (17). A brief outline is described below.
Serum samples
One ml of serum was used for analysis in triplicate of 2 H enrichment in body water by continuous flow IRMS following equilibration with H 2 gas (19). One ml of each serum sample was deproteinsed by ultrafiltration prior to analysis of free amino acid enrichment. Plasma free amino acids were purified by cation exchange and prepared for GC-pyrolyis-IRMS analysis as ethoxy carbonyl ethyl esters (17). Basal deuterium abundance in protein-bound alanine from serum albumin was measured (20) and assumed to be equal to basal abundance in myofibrillar protein (21) .
Processing of muscle biopsies
Rectus and quadriceps skeletal muscle biopsies were processed to isolate the myofibrillar component.
Muscle biopsies of ~30µg were homogenised on ice and centrifuged at 10,000 x g for 15 minutes. The supernatant underwent serial Triton x-100 washes and centrifugation with the myofibrillar pellet being retained. Rectus abdominis muscle was additionally processed for recovery of free intracellular amino acids. After homogenisation and centrifugation the initial supernatant was processed for separation of free intracellular amino acids by ultrafiltration. Myofibrillar protein isolates (~2 mg) were subjected to gas phase acid hydrolysis ( 
Body composition
Deuterium dilution space was calculated from the intercept of the elimination plot divided by the dose, following the methodology as used in the doubly-labelled water protocol (22). Total body water (TBW) was calculated from deuterium space assuming non-aqueous hydrogen exchange factor of 1.041. Fat free mass was calculated from TBW by assuming FFM hydration was 73.2% (23) . Skeletal muscle mass (SMM; kg) was estimated from FFM using the MRI-validated equations of Wang (24) which describe the ratio of SMM:FFM with gender and age. A myofibrillar protein content of 12.4% SMM was assumed (25).
CT measures of body composition
Cross sectional measures of muscularity were taken from routine CT scans in patients in the preoperative period according to the previously described method (26) . Muscle CSA was measured with SliceOmatic V4.3 software (Tomovision, Canada). In order to provide clinical context and to allow comparison with total body water measures of body composition, cross sectional measurements were converted to whole body estimates of FFM using the formula of Mourtzakis et. al (26) . Muscle mass 
Statistics
Statistical analysis was performed using SPSS v21. Group data are presented as median and range.
Group comparisons were made using either Mann-Whitney U test or Wilcoxon Signed Ranks Test for paired data. Comparison across multiple groups was performed using the Jonckheere-Terpstra trend test for non-parametric data where the groups have order (27, 28) . Correlations were tested by Spearman's rho.
Results
Group characteristics
Seven healthy volunteers and 14 patients with 'resectable' upper GI cancer were recruited. There were 9 patents with oesophageal cancer (pT1-3, N0-2) and 5 patients with gastric cancer (pT1-4, N0-2). 11/15 patients had undergone pre-operative neo-adjuvant chemotherapy. All patients were studied at least 4 weeks after their last dose of chemotherapy. The patient group was stratified into weight-stable and weight-losing groups using weight loss ≥5%. Group characteristics are described in Table 1 . Groups were well matched with the exception of age in the weight-losing cancer group who were slightly older.
Research. 
Skeletal muscle myofibrillar protein FSR
When patients were categorised by weight loss, there was a trend in quadriceps myofibrillar protein FSR across all three groups (Healthy controls < weight stable patients with cancer < weight losing patients with cancer) (p=0.022). Quadriceps FSR was higher in weight-losing patients with cancer (0.073 % per hour) compared with healthy volunteers (0.058% per hour) (Figure 1 ) (p=0.03).
Baseline body composition and pre-op loss of skeletal muscle mass
CT scans were undertaken immediately prior to surgery for all 14 patients with cancer. A measure of skeletal muscle cross sectional area at the level of the third lumbar vertebrae was available for each.
Of these 14 patients, 9 were classified with low muscularity and 5 were classified as myosteatotic.
Sequential scans were available in 10 patients with a mean interval time of 79 days. Summary baseline (i.e. before neoadjuvant chemotherapy) body composition measures are shown in Table 2 .
Over the subsequent 79 days, all but one patient lost muscle mass. Median muscle loss was 5.6%/100d. There was no correlation between muscle loss and muscle FSR using either quadriceps or rectus measures (p=0.531, p=0.940).
Myofibrillar protein synthesis and breakdown
Skeletal muscle FBR was not different between weight-stable (n=3, FBR -0.056%hr, range -0.049 to -0.067) and weight-losing patients with cancer (n=7, FBR -0.061, range -0.037 to -0.075) (p=0.833 ).
Skeletal muscle mass estimated from deuterium dilution in only those cancer patients who underwent serial CT scans is given in be calculated in the patients in comparison with the control subjects, who were assumed to have stable muscle mass (thus, FSR=FBR). These early stage cancer patients showed similar muscle mass to controls and similar level of relative (FSR) and absolute myofibrillar protein synthesis (Table 3 ). In the cancer patients, myofibrillar protein breakdown was just 1.2 g/day (2.9%) greater than synthesis.
Discussion
The present study found that habitual skeletal muscle protein FSR tended to be higher in weightlosing versus either weight-stable cancer patients or healthy controls. These findings contradict the hypothesis that muscle wasting in cancer cachexia is caused by a reduction in protein synthesis. The present study is the first to measure skeletal muscle protein FSR during a period of days/weeks that incorporates the physiological variations associated with feeding/fasting and activity/rest. The finding supports our previous studies in similar patients with early stage (resectable) upper GI cancer that had shown normal physical activity levels (29) and relative preservation of protein intake (30) exercise and amino acids being two of the key stimuli for protein synthesis in skeletal muscle.
Two previous short term studies (<6 hours) using a primed constant infusion of isotope tracer have shown that skeletal muscle protein FSR may be reduced in the fed state in patients with lung cancer (9) or may be unchanged (colorectal cancer) but with a blunted response to intravenous infusion of amino acids (2) . Any potential reduction in muscle protein FSR would be expected to be more apparent during the present protocol than during a short term infusion protocol as the oral tracer design incorporates the potentially cumulative anabolic effect of many meals over the one week protocol. As a result, there appears to be a genuine contradiction between the results of the current study and those of the previous infusion tracer studies. In previous studies, we have demonstrated that in patients with upper GI cancer cachexia there is predominant downregulation of the transcriptome in human muscle consistent with a reduction in cell turnover/protein synthesis (10) . The present study demonstrates a potential disconnect between regulatory pathways in the transcriptome and the gross level of protein synthesis in the myofibre.
Studies in small animals have suggested a central role for AKt (Protein Kinase B) signalling and the regulation of skeletal muscle protein synthesis. However, when considered in humans, there appears to be a dissociation between cell signalling (AKT) and myofibrillar protein synthesis during feeding, exercise and immobilisation (31) . No investigation of the cellular mechanisms of protein synthesis or degredation were performed during this study so it is only possible to speculate on possible explanations for the differences found between groups. One possible mechanism to account for such divergent findings is the presence of an alternative pathway sensitive to acute physiological change/damage such as regenerative myogenesis. Indeed, muscle mass may be influenced by the balance between myofibre loss (apoptosis/autophagy) and myocyte regeneration from satellite cells.
In muscle biopsies from weight-losing patients with upper gastro-intestinal cancer we have shown a threefold increase in muscle DNA fragmentation compared with control subjects. The increase in DNA laddering was associated with an increase in poly(ADP-ribose) polymerase (PARP) cleavage, both observations being consistent with enhanced apoptosis (32) . Concerning muscle regeneration, He and co-workers (33) have recently described in both tumour-bearing mice and patients with pancreatic cancer, activation of both satellite and non-satellite muscle progenitor cells. However, there appeared to be a downstream block to regeneration via NFkB-mediated Pax7 dysregulation and this was thought to contribute to net muscle atrophy.
In a recent study Williams and co-workers (3) assessed myofibrillar FSR in both the fasting and postabsorptive state. The expected increase of FSR with feeding was observed in the control subjects but was lost in patients with cancer. This finding suggests that muscle wasting in cancer cachexia could occur due to a blockade to normal anabolic stimuli and highlights the importance of considering the In the present study the median muscle loss was 5.6% per 100 days prior to surgery. In the group of 10 cancer patients with serial CT measurements, median body weight was 71 kg and median muscle mass was 20.2 kg (Table 3 ). In the cancer patients, median myofibrillar protein synthesised per day was 41.2 g (Table 3 ). Median myofibrillar protein breakdown was estimated to be 42.4 g/day, or 1.2g/day (2.9 %) greater than synthesis. In the context of whole body protein synthesis, myofibrillar protein may account for 20-25%, with mixed muscle protein contributing 33-40% of total body protein synthesis. The imbalance between breakdown and synthesis of only 2.9% is perhaps the most important observation. Such a small, but vitally important imbalance between synthesis and breakdown is difficult to quantify. Accurate assessment of the situation necessitates long term measures of myofibrillar protein synthesis along with serial measurements of muscle mass on an individual basis. Only then will it be established if these observations can be generalised and if they relate to the disease stage studied.
One explanation of loss of skeletal muscle could be due to modestly increased degradation. Direct measures of skeletal muscle degradation using arterio-venous difference methodology has shown increased degradation in patients with cancer compared with controls (2). Skeletal muscle synthetic and degradative pathways are closely dependent. Conventionally this interdependence is understood to reduce synthesis when degradation is increased and vice versa (35). However, this interaction appears to be more complex, even in health where increased muscle breakdown is seen in response to
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on October 16, 2017. © 2014 American Association for Cancer clincancerres.aacrjournals.org Downloaded from the anabolic stimulus of resistance or endurance exercise (36) . As such, it is possible that the changes seen in cachectic muscle reflect a process of deranged skeletal muscle remodelling where synthesis is necessarily increased but counter-acted by increased muscle degradation. Alternatively the increased synthesis could be the result of an inadequate compensatory mechanism to balance pathological muscle breakdown. In mice, increased skeletal muscle FSR in the presence of net loss of muscle protein occurs during denervation induced muscle wasting (37) (38) (39) (40) (41) . The mechanism for an increase in muscle synthesis during net protein loss could be through stimulation of protein synthesis via mTORC1. This protein complex, normally associated with the maintenance of muscle mass and muscle hypertrophy could be activated by the increase in amino acids released as a result of increased protein breakdown by the proteasome (41) . In a murine model of cancer cachexia, increased levels of phosphorylated Akt and increased exression IGF-1 in muscle of tumour bearing AH-130 and C26 mice suggests that muscle wasting in tumour bearing animals may not be associated with down regulation of molecules involved in the anabolic response (42) In further support of a counterregulatory response to compensate for muscle loss in cachexia, Op den Kamp and co-workers (43) have recently observed increased Akt phosphorylation in the muscle of cachectic lung cancer patients.
However, downstream phosphosubstrates glycogen synthase kinase 3β, MTORC and Forkhead box protein were unaltered and this may be evidence for overall impaired anabolic signalling.
Furthermore, these complex interactions may alter with disease stage.
There are a number of potential limitations to the present study. First, the number of patients and volunteers was relatively small and matching treatment effects, diet and exercise was not possible..
The small numbers resulted in groups that were not matched exactly for age (i.e. the patient group was older than the volunteer group). However, it is unlikely that a difference between the groups is masked as older individuals are likely to have a reduced FSR or reduced response to anabolic stimuli (44, 45) . The patient group had undergone neoadujvant chemotherapy. The regimens used (either cisplatin and 5 Fluorouriacil or epirubacin, cisplatin and capecitabine) are not known to increase protein synthesis and have previously been associated with loss of muscle mass (46) (47) . The magnitude of the difference in FSR between quadriceps and rectus is, however, small and the clinical significance of the finding is uncertain. It does, however, demonstrate the importance of comparing the same muscle between subject groups and that the technique can detect small differences in FSR.
In conclusion, myofibrillar skeletal muscle FSR measured in free living individuals over the period of one week is not reduced in patients with cancer compared with healthy volunteers. These findings Table 3 -Skeletal muscle mass (kg), absolute myofibrillar protein synthesis and absolute myofibrillar protein breakdown (g/day). Cancer patients with serial CT scans are included (n=10; comprising 7 weight losing and 3 weight stable subjects). Muscle mass was estimated at the time of consuming deuterium oxide. Control subjects (n=7) were assumed to have stable muscle mass. Protein kinetics were derived from quadriceps biopsy data. 
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